We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Test Detects Early Colorectal Adenomas

By LabMedica International staff writers
Posted on 08 Feb 2021
Print article
Image: Photomicrograph of a moderately differentiated colorectal carcinoma with dirty necrosis (Photo courtesy of Mikael Häggström, MD).
Image: Photomicrograph of a moderately differentiated colorectal carcinoma with dirty necrosis (Photo courtesy of Mikael Häggström, MD).
Colonoscopies are the gold standard for screening but have low compliance rates due to the invasiveness of the procedure. Stool-based tests have poor compliance and low sensitivity for advanced adenomas (AA), at about 24% to 42%.

Many of the 50,000 annual colorectal cancer (CRC) deaths can be attributed to 1/3 eligible Americans not following screening guidelines or approximately 1/2 of the population not adherent to the follow-up post-polypectomy guidelines. The new understanding of the natural history and shared etiology of adenomas and CRC inform integration of clinically relevant biomarkers.

Medical Scientists at the Stanford University Medical Center (Stanford, CA, USA) and their colleagues conducted a prospective, blinded study of 458 individuals who had their blood drawn prior to undergoing colonoscopy and who had no prior history of colorectal cancer. Of them, 239 individuals underwent screening colonoscopy and 219 underwent surveillance colonoscopy. Most of the individuals (86%) were asymptomatic, whereas 14% had symptoms or a positive fecal immunochemical test.

The team developed the FirstSight blood test (CellMax Life, Sunnyvale, CA, USA) to detect adenoma-carcinoma pathways in blood samples based on the presence of circulating gastrointestinal epithelial cells and somatic mutations of cell-free tumor DNA. The test analyzes two biomarkers: circulating gastrointestinal epithelial cells and somatic mutations of cell-free DNA. The probability of advanced neoplasia was obtained by ordinal/nominal logistic regression methods together with SEER-incidence rate and prior history of AA on a training set of 346 subjects. A cutpoint was selected to obtain a test specificity (non-neoplastic finding or negative colonoscopy) of 90% resulting in a sensitivity of 100% and 80.0% for detection of CRC and advanced neoplasia (AN = CRC+AA), respectively, on the training subjects.

The investigators reported that the area under the ROC curve is 0.91. Validation using the fixed cutpoint and 112 test subjects achieved 91.4% specificity and 100% and 75.0% sensitivity for CRC and AN. Shai Friedland, MD, a Professor of Gastroenterology and his colleagues concluded that “This blood test has high sensitivity for colorectal advanced neoplasia while retaining high specificity. The quantitative nature of the score has the potential to enable prognostic stratification of patients for screening or post-polypectomy surveillance colonoscopy.” The study was presented at the Gastrointestinal Cancers Symposium (virtual meeting); held January 15-17, 2021.

Related Links:
Stanford University Medical Center
CellMax Life


New
Gold Supplier
SARS-CoV-2 Multiplex Real-Time RT-PCR Assay
GSD NovaPrime Plus SARS-CoV-2
New
Direct-to-PCR Workflow for SARS-COV-2 Detection
Direct to PCR SARS-COV-2 Solution
New
Cartridge Incubator
WS-i60 Cartridge Incubator
New
Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20

Print article

Channels

Industry

view channel
Illustration

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.